Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

por McLellan, B., Ciardiello, F., Lacouture, M. E., Segaert, S., Van Cutsem, E.
Publicado 2015

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

por Joulain, F, Proskorovsky, I, Allegra, C, Tabernero, J, Hoyle, M, Iqbal, S U, Van Cutsem, E
Publicado 2013

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 tria...

por Okines, A, Puerto, O del, Cunningham, D, Chau, I, Van Cutsem, E, Saltz, L, Cassidy, J
Publicado 2009

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life

por Van Cutsem, E., Kato, K., Ajani, J., Shen, L., Xia, T., Ding, N., Zhan, L., Barnes, G., Kim, S.-B.
Publicado 2022

Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer

por Roeyen, G., Berrevoet, F., Borbath, I., Geboes, K., Peeters, M., Topal, B., Van Cutsem, E., Van Laethem, J.-L.
Publicado 2022

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

por Cunningham, D, Wong, R P W, D'Haens, G, Douillard, J-Y, Robertson, J, Stone, A M, Van Cutsem, E
Publicado 2013

A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system

por Coolbrandt, A., Tobback, H., Govaerts, R., Vandezande, L., Vinckx, M., Laenen, A., Wildiers, H., Verslype, C., Dekervel, J., Van Herpe, F., Van Cutsem, E.
Publicado 2023

Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma

por Falk, S, Anthoney, A, Eatock, M, Van Cutsem, E, Chick, J, Glen, H, Valle, J W, Drolet, D W, Albert, D, Ferry, D, Ajani, J
Publicado 2006

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

por Macarulla, T, Cervantes, A, Tabernero, J, Roselló, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B, Jego, V, von Richter, O, Ciardiello, F
Publicado 2015

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

por Punt, C.J.A., Heinemann, V., Maughan, T., Cremolini, C., Van Cutsem, E., McDermott, R., Bodoky, G., André, T., Osterlund, P., Teske, A.J., Pfeiffer, P.
Publicado 2023

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorec...

por Tabernero, J., Grothey, A., Arnold, D., de Gramont, A., Ducreux, M., O’Dwyer, P., Tahiri, A., Gilberg, F., Irahara, N., Schmoll, H.-J., Van Cutsem, E.
Publicado 2022

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

por Kelley, R. K., Verslype, C., Cohn, A. L., Yang, T.-S., Su, W.-C., Burris, H., Braiteh, F., Vogelzang, N., Spira, A., Foster, P., Lee, Y., Van Cutsem, E.
Publicado 2017

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

por Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Publicado 2005

Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis

por Yoshino, T., Van Cutsem, E., Li, J., Shen, L., Kim, T.W., Sriuranpong, V., Xuereb, L., Aubel, P., Fougeray, R., Cattan, V., Amellal, N., Ohtsu, A., Mayer, R.J.
Publicado 2022

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

por Siena, S, Peeters, M, Van Cutsem, E, Humblet, Y, Conte, P, Bajetta, E, Comandini, D, Bodoky, G, Van Hazel, G, Salek, T, Wolf, M, Devercelli, G, Woolley, M, Amado, R G
Publicado 2007

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial

por Verstraete, M, Debucquoy, A, Dekervel, J, van Pelt, J, Verslype, C, Devos, E, Chiritescu, G, Dumon, K, D'Hoore, A, Gevaert, O, Sagaert, X, Van Cutsem, E, Haustermans, K
Publicado 2015

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCEN...

por Taieb, J., Shi, Q., Pederson, L., Alberts, S., Wolmark, N., Van Cutsem, E., de Gramont, A., Kerr, R., Grothey, A., Lonardi, S., Yoshino, T., Yothers, G., Sinicrope, F.A., Zaanan, A., André, T.
Publicado 2019

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

por Tabernero, J., Velez, L., Trevino, T.L., Grothey, A., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S.
Publicado 2021

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

por Van Cutsem, E., Hochster, H., Shitara, K., Mayer, R., Ohtsu, A., Falcone, A., Yoshino, T., Doi, T., Ilson, D.H., Arkenau, H.-T., George, B., Benhadji, K.A., Makris, L., Tabernero, J.
Publicado 2022

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis

por De Smedt, L, Lemahieu, J, Palmans, S, Govaere, O, Tousseyn, T, Van Cutsem, E, Prenen, H, Tejpar, S, Spaepen, M, Matthijs, G, Decaestecker, C, Moles Lopez, X, Demetter, P, Salmon, I, Sagaert, X
Publicado 2015